#Canada #Montreal #Heart Failure #Thryv Therapeutics #SGK1 Inhibitor

Introduction

Thryv Therapeutics Inc., a clinical-stage biopharmaceutical firm headquartered in Montreal, Quebec, has recently gained attention for its innovative research in treating heart failure, particularly heart failure with reduced ejection fraction (HFrEF). The company's lead SGK1 inhibitor, THRV-1268, has shown promise in preliminary studies, and now new findings from an article published in JACC Heart Failure present a compelling case for advancing this treatment into Phase 2a clinical development.

Background on Heart Failure and SGK1 Inhibition

Despite progress in guideline-directed medical therapies (GDMT), patients suffering from HFrEF continue to encounter substantial risks. Roughly 40% of recently hospitalized patients prescribed quadruple GDMT experience hospital readmissions or fatalities within a year. This alarming statistic highlights the urgent need for novel therapeutic strategies. SGK1 (serum/glucocorticoid-regulated kinase 1) has emerged as a crucial target in this context. Scientific investigations demonstrate that SGK1 plays a role in metabolic stress, inflammation, fibrosis, and electrical remodeling in cardiac tissues.

Study Highlights

The publication titled "Genetic, Preclinical, and Clinical Evidence Supports SGK1 Inhibition in Heart Failure" encapsulates findings from human genetic, preclinical, and clinical studies.

1. Genetic Data Insights: The research elucidates strong genetic correlates linking SGK1 expression to heart failure risk. Notably, individuals with a genetic variation that leads to reduced SGK1 expression in the heart show a lower incidence of heart failure. Elevated SGK1 levels are consistently observed in several types of cardiomyopathies, emphasizing its significance as a therapeutic target.

2. Animal Model Efficacy: In preclinical models, THRV-1268 not only preserved critical cardiac functions but also outperformed empagliflozin, a standard monotherapy, in multiple assessments. In studies that extended to day 56, THRV-1268 demonstrated superior performance in maintaining systolic function and mitigating adverse remodeling in the heart.

3. Safety Profile: The safety data from two placebo-controlled Phase 1 studies revealed that THRV-1268 maintained a neutral hemodynamic profile and demonstrated favorable outcomes concerning QTcF shortening, indicating cardiac target engagement. The safety tolerance attributed to THRV-1268 positions it uniquely among potential heart failure therapies.

Strategic Advancements

Given these results, Thryv announced the initiation of the ASPIRE-HF study, expected to begin enrolling patients in Q4 2026. This Phase 2a trial aims to evaluate the safety, pharmacokinetics, and clinical outcomes of THRV-1268 in individuals with symptomatic HFrEF and QTc prolongation, who face persistent risks for arrhythmias and worsening heart conditions.

Conclusion

The convergence of genetic data and the targeted action of SGK1 inhibition supports Thryv's strategy to further develop THRV-1268. Given the persistent challenges in treating heart failure effectively, advancements in SGK1 inhibition could provide a breakthrough for patients enduring the complexities of HFrEF. With promising findings and an ambitious roadmap ahead, Thryv Therapeutics exemplifies innovation in the biopharmaceutical landscape, marking an essential step forward in heart failure management.

For further details, the full study can be accessed at ScienceDirect.